Welcome to San Francisco Biotech Networks DAILY for 01/11/2026. Daily news and jobs are listed below. Please forward this email to your colleagues so they can subscribe at biotechnetworks.org/daily

​​​​​​​

Click a link below to view the mailing archive as if it had been sent to you.

2020-12-31 01:30Why these 19 Bay Area biotech stories from 2020 are important to me
2020-12-30 01:30It's official: Vir Biotechnology scoops up portion of Dropbox sublease at Mission Bay HQ and more...
2020-12-29 01:30With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs and more...
2020-12-24 01:3010x Genomics to Present at the 39th Annual J.P. Morgan Healthcare Conference and more...
2020-12-23 01:30FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 and more...
2020-12-22 01:30XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering and more...
2020-12-21 01:30GlaxoSmithKline joins Sosei's who's-who list of clients with global licensing pact for IBD small molecules
2020-12-20 01:30Pacific Biosciences Grants Equity Incentive Award to New Employee and more...
2020-12-19 01:30After 20 years and founder's sudden death, S.F. biotech wins 1st FDA drug approval and more...
2020-12-18 01:30Model N to Acquire Deloitte’s Life Sciences Pricing and Contracting Solutions Business and more...
2020-12-17 01:30Napa, San Mateo and Solano counties forced into Covid shutdown and more...
2020-12-16 01:30It’s official: Gilead’s Dan O’Day pulls the plug on the lion’s share of their filgotinib collaboration as the FDA erects a high safety barrier. What went wrong? and more...
2020-12-15 01:30Neuroscientists tap gamers to learn how people problem-solve and more...
2020-12-13 01:30IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-12-12 01:30Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares and more...
2020-12-11 01:30Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock and more...
2020-12-10 01:30Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer and more...
2020-12-09 01:30Sutro Biopharma Announces Pricing of $126.0 Million Public Offering and more...
2020-12-08 01:30How a Peninsula company puzzled out a new biotech model around potential eye, heart drugs and more...
2020-12-07 01:30Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
2020-12-06 01:30#ASH20: Gilead reads out PhII data to back CAR-T player Yescarta in a new indication and more...
2020-12-05 01:30U.S. House passes historic cannabis legalization bill and more...
2020-12-04 01:30One biotech's odd journey to go public clears path to treat crippling conditions and more...
2020-12-03 01:30Twist Bioscience Announces Pricing of a $300 Million Upsized Public Offering of Common Stock and more...
2020-12-02 01:30Two local biotechs harvest top-level execs from Genentech and more...
2020-12-01 01:30After $700 million and another round of layoffs, Peninsula biotech's 22-year run nears end with merger and more...

 

<< Archive Index • Subscribe >>

 

© Biotech Networks. You're receiving this email because you've signed up to receive updates from us.

If you'd prefer not to receive updates, you can unsubscribe.
 
© FeedBlitz® - Win the Inbox ™ | feedblitz.com | info@feedblitz.com | Privacy | Terms of Service
 English | Português | Français | Español | Italiano | Nederlands | Svenska | Deutsch | 日本語